Bringing the Oncology Community Together
Giants of Cancer Care 2015
Hodi Speaks to Significance of Phase II Data on Ipilimumab Plus Nivolumab in Melanoma
OncLive sat down with F. Stephen Hodi, director, Melanoma Center, director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, to gain further insight into combination and sequencing strategies for patients with melanoma.
Generic Chemotherapies Recalled by Manufacturer
The generics and specialty manufacturer Mylan has recalled several chemotherapy agents, including gemcitabine, carboplatin, methotrexate, and cytarabine, due to the presence of visible foreign particulates.
CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALL
The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
FDA Approves Second-Line Ramucirumab for mCRC
The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer following progression an upfront bevacizumab-containing regimen.
FDA Updates Pomalidomide Multiple Myeloma Label
The FDA has updated the label for pomalidomide plus low-dose dexamethasone to include data from the phase III MM-003 study.
Ibrutinib Response Rates Improve With Longer Follow-Up in CLL
Single-agent ibrutinib demonstrated an overall response rate of 91%, including a complete response rate of 14%, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Inotuzumab Ozogamicin Improves Response Rates Versus Chemotherapy in Phase III ALL Study
Treatment with the antibody-drug conjugate inotuzumab ozogamicin significantly extended complete hematologic remission rates compared with chemotherapy for adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia,
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.